Freeline Therapeutics company
Freeline Therapeutics is a biopharmaceutical company that develops liver directed gene therapies for bleeding disorders and other diseases. Its therapies are based on next-generation proprietary AAV vector platform, with its lead program being a gene therapy to treat haemophilia B.
Freeline Therapeutics was founded in 2015 and is headquartered in London, England.
Founded Date:
2015
Total Funding:
$276M
Investor Type:
Company
Employee Number:
11-50
Investment Stage:
N/A
Funding Status:
Early Stage Venture
Number Of Exists:
Series C
Technology:
P4 Medicine
Last Funding Type:
Series C
Investors Number:
9
Industry:
Personalized Medicine
Headquarters:
Stevenage, Herefordshire, United Kingdom
Estimated Revenue:
$1M to $10M